Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's disease2 (KBASE2)

NCT05138263 · tracked via the Priya Life Science South Korea tracker
Phase
Observational
Started
2022-01-01
Last updated
2026-05-27

Condition(s) studied

Alzheimer DiseaseMild Cognitive Impairment

Study summary

The KBASE2 is the second phase of the KBASE project, which consists of roll-over participants from the first phase of the KBASE as well as newly enrolled participants with varying degrees of cognitive functions (e.g. individuals with normal cognition, mild cognitive impairment, or AD dementia). In addition to the aims of the first phase of the KBASE, the KBASE2 will focus on new data collection and integrative analysis of the rich structural, functional, and molecular neuroimaging data in relation to whole genome sequencing and other -omics. Network analysis of disruption in brain connectivity in relation to clinical status and AD biomarker profiles also will be conducted.

Eligibility

Sex
ALL
Min age
20 Years
Max age
90 Years
Healthy volunteers
Accepted
Participants will be classified as either Alzheimer's disease(AD) group, mild cognitive impairment(MCI) group, elderly normal controls or young normal controls. Specific inclusion criteria for each group is described below. Inclusion Criteria: \[Inclusion criteria: AD\] * Age : 55 - 90 * Clinical Dementia Rating (CDR)=0.5 or 1 * Diagnostic and Statistical Manual-IV(DSM-IV) criteria for dementia * National Institute of Aging and the Alzheimer's Association (NIA-AA) Probable AD dementia * Study partner or caregiver to accompany patient to all scheduled visits * Written informed consent \[Inclusion criteria: MCI (amnestic)\] * Age : 55 - 90 * Clinical Dementia Rating (CDR)=0.5 * Concern regarding a change in cognition (obtained from the subject, from an informant who knows the subject, or from a skilled clinician observing the subject) * Lower performance in any cognitive domain that is greater than would be expected for the subject's age and educational background * Preservation of independence in functional abilities * Study partner or caregiver to accompany subject to all scheduled visits * Written informed consent \[Inclusion criteria: Elderly normal controls\] * Age : 55 - 90 * Clinical Dementia Rating (CDR)=0 * Those with contactable Informant * Written informed consent \[Inclusion criteria: Young normal controls\] * Age : 20 - 54 * Clinical Dementia Rating (CDR)=0 * Written informed consent Exclusion Criteria: \[Exclusion criteria: general\] * Past history or presence of major psychiatric illness (e.g. schizophrenia, bipolar disorder, alcohol/substance abuse or dependence, delirium) * Significant neurologic or medical condition that can influence the mental state * Contraindications for MRI scan (e.g. pacemaker, claustrophobia) * Illiteracy * Significant visual or hearing difficulty * Taking investigational drug * In pregnancy or breast-feeding

Primary outcome measure(s)

  • Amount of brain amyloid deposition — baseline
    Group difference in baseline brain amyloid deposition on florbetaben PET and the relationship between the amount of brain amyloid deposition and clinical, neuropsychological, neuroimaging, genetic, biochemical measurement will be investigated.
  • Amount of brain tau deposition — baseline
    Group difference in baseline brain amyloid deposition on AV1451 PET and the relationship between the amount of brain tau deposition and clinical, neuropsychological, neuroimaging, genetic, biochemical measurement will be investigated.

Trial sites (2)

FacilityCityRegionStatus
SMG-SNU Boramae Medical Center Seoul Seoul
Seoul National University Hospital Seoul South Korea
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05138263 on ClinicalTrials.gov ↗ ← All trials in South Korea